Physician profile
Ashlee Dauscha
NPI 1710643523
$2,516.75
in general payments reported to CMS, 2019-2025
23 companies · $933 in 2025
The $933 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,075 · 2023: $151 · 2024: $358 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Education: $17.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.48 |
| Education | $17.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $619.92 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $574.86 | 2022-2025 | |
| Novo Nordisk INC | $193.30 | 2022-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $160.54 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $155.68 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.36 | 2022-2024 | Caplyta |
| Viiv Healthcare Company | $124.99 | 2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $122.76 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Amgen INC. | $77.13 | 2022 | |
| Gilead Sciences, INC. | $60.38 | 2024-2025 | |
| Lilly USA, LLC | $43.50 | 2022-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.72 | 2022 | |
| Nevro Corp. | $25.17 | 2022 | |
| Shield Therapeutics INC | $24.14 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.43 | 2025 | Lifevest |
| Pfizer INC. | $19.13 | 2024 | |
| Lucid Diagnostics INC. | $19.13 | 2024 | |
| Neurocrine Biosciences, INC. | $16.97 | 2022 | |
| Abbott Laboratories | $16.59 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $16.55 | 2024 | |
| Renalytix Ai, INC. | $15.79 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Dauscha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.